,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-10-15 03:52:00,"Medical device major, St. Jude Medical ( STJ ) is slated to announce its third quarter results before the opening bell on Wednesday, October 17.",0.044868167489767075,0.007697781547904015,0.9474340677261353,neutral,0.03717038780450821
1,2012-10-15 03:52:00,"The current Zacks Consensus Estimate for the third quarter is 80 cents, representing estimated year-over-year growth of 3.13%.",0.8597556352615356,0.016496911644935608,0.12374740839004517,positive,0.8432587385177612
2,2012-10-15 03:52:00,St. Jude's second-quarter 2012 adjusted earnings per share of 88 cents beat the Zacks Consensus Estimate by a penny and exceeded the year-ago earnings of 85 cents.,0.9364585280418396,0.04326307401061058,0.020278392359614372,positive,0.8931954503059387
3,2012-10-15 03:52:00,"In the quarter, reported profit inched up 1.2% to $244 million (or 78 cents a share) as lower expenses offset weak revenue generation.",0.9442904591560364,0.039099857211112976,0.01660964824259281,positive,0.9051905870437622
4,2012-10-15 03:52:00,"The Minnesota-based medical technology giant reported net revenues of $1,410 million, down 2% year over year, beating the Zacks Consensus Estimate of $1,430 million.",0.018852200359106064,0.9713322520256042,0.009815534576773643,negative,-0.9524800777435303
5,2012-10-15 03:52:00,Sustained poor performance across the Cardiac Rhythm Management (CRM) unit and the vascular unit more than offset growth at the company's smaller Atrial Fibrillation (AF) and Neuromodulation franchises.,0.025363652035593987,0.9636335372924805,0.011002857238054276,negative,-0.9382699131965637
6,2012-10-15 03:52:00,"Revenues from the core CRM segment dropped 6% year over year to $746 million, indicating continued softness in the CRM market.",0.016521308571100235,0.9739395976066589,0.009539111517369747,negative,-0.9574182629585266
7,2012-10-15 03:52:00,"Implantable Cardioverter Defibrillator (""ICD"") revenues dipped 4%, while pacemaker sales declined 9%.",0.01932573691010475,0.971936821937561,0.008737413212656975,negative,-0.9526110887527466
8,2012-10-15 03:52:00,"However, AF revenues grew 5%, but sales were affected by slower uptake of AF capital equipment, indicating a tough hospital spending scenario.",0.10725763440132141,0.8714869022369385,0.021255450323224068,negative,-0.7642292976379395
9,2012-10-15 03:52:00,"Neuromodulation sales increased 2%, led by new products launches.",0.9563688635826111,0.021361321210861206,0.022269709035754204,positive,0.9350075721740723
10,2012-10-15 03:52:00,"The Cardiovascular franchise inched down 1%, reflecting the impact of a termination of a vascular products distribution contract in Japan.",0.017465410754084587,0.9726427793502808,0.009891885332763195,negative,-0.955177366733551
11,2012-10-15 03:52:00,There is a moderate positive bias in estimate revisions for both the September quarter and the full year.,0.1952073574066162,0.020827513188123703,0.7839651107788086,neutral,0.1743798404932022
12,2012-10-15 03:52:00,The past 7 days have seen one of eighteen estimates rise for the quarter and none moving in the opposite direction.,0.2848673164844513,0.08510113507509232,0.6300315260887146,neutral,0.19976618885993958
13,2012-10-15 03:52:00,"The past 30 days have seen two of eighteen estimates rise for the quarter, and one estimate moved in the opposite direction in the same period.",0.1733473837375641,0.09066037088632584,0.7359922528266907,neutral,0.08268701285123825
14,2012-10-15 03:52:00,"The past 7 days have seen one of nineteen estimates rise for the full year 2012 move north, while none moving in the opposite direction.",0.20815882086753845,0.12377770245075226,0.6680634617805481,neutral,0.0843811184167862
15,2012-10-15 03:52:00,"The past 30 days have seen three of nineteen estimates rise for the year, and one estimate moved in the opposite direction in the same period.",0.17781803011894226,0.07067541033029556,0.7515065670013428,neutral,0.1071426197886467
16,2012-10-15 03:52:00,"Estimates for both the third quarter and full year remained unchanged at 80 cents per share and $3.43, respectively, over the past week and month.",0.07382895052433014,0.5317679643630981,0.39440304040908813,negative,-0.4579390287399292
17,2012-10-15 03:52:00,"The current Zacks Consensus Estimate for full-year 2012 is $3.43 per share, representing an estimated year-over-year growth of 4.61%.",0.9508267045021057,0.019051721319556236,0.03012150712311268,positive,0.9317749738693237
18,2012-10-15 03:52:00,"With respect to earnings surprises, St. Jude has posted positive surprises in the preceding four quarters.",0.9324065446853638,0.02790195122361183,0.039691582322120667,positive,0.9045045971870422
19,2012-10-15 03:52:00,"It has delivered an average positive earnings surprise of 2.44% over the past four quarters, implying that the company has surpassed the Zacks Consensus Estimate by that measure.",0.9523043632507324,0.023888710886240005,0.023806914687156677,positive,0.9284156560897827
20,2012-10-15 03:52:00,Third quarter earnings are also expected to meet expectations.,0.9308539032936096,0.016399700194597244,0.05274632200598717,positive,0.9144542217254639
21,2012-10-15 03:52:00,"With a market cap of $13.37 billion, St. Jude is a leading medical device manufacturer with a solid rate of growth over the past decade.",0.9177351593971252,0.013004080392420292,0.06926074624061584,positive,0.9047310948371887
22,2012-10-15 03:52:00,We believe that new product development and penetration into emerging markets will drive long-term growth for the company.,0.9232527613639832,0.012401225976645947,0.06434594839811325,positive,0.9108515381813049
23,2012-10-15 03:52:00,"Moreover, stabilizing trend in the U.S. ICD market and St. Jude's continuing market share gain in the ICD space, despite the Riata lead problem, is a positive sign.",0.9446969032287598,0.017260057851672173,0.038043029606342316,positive,0.9274368286132812
24,2012-10-15 03:52:00,"New products such as the Quadra, Ellipse, EnligHTN, Accent MRI as well as the transaortic valve replacement (TAVR) and the percutaneous mitral valve repair (PMVR) will drive market share gains and above-market growth.",0.948975682258606,0.017016345635056496,0.03400808200240135,positive,0.931959331035614
25,2012-10-15 03:52:00,"Moreover, recently released positive data from the FAME II clinical trial is expected to further expand the growth opportunity for the Fractional Flow Reserve (FFR) technology.",0.942155659198761,0.015122422948479652,0.042722031474113464,positive,0.9270332455635071
26,2012-10-15 03:52:00,"Recently, St. Jude announced that it is consolidating its four operating segments into two units to reduce operating expenses as a necessary measure to hedge against the upcoming MedTech tax from 2013.",0.7459884881973267,0.01883820816874504,0.2351733148097992,positive,0.7271502614021301
27,2012-10-15 03:52:00,The company also changed the executive heads leading the business segments and eliminated roughly 300 employees in the process.,0.016192380338907242,0.9392139315605164,0.04459362104535103,negative,-0.9230215549468994
28,2012-10-15 03:52:00,"However, St. Jude expects a weak Euro, competitive pressures and risk of a sluggish market, given the ongoing difficult macroeconomic conditions to be a drag on the company's results.",0.037696316838264465,0.8471918106079102,0.11511190235614777,negative,-0.8094955086708069
29,2012-10-15 03:52:00,St. Jude and its peers Medtronic Inc. ( MDT ) and Boston Scientific Corporation ( BSX ) are contending in a soft CRM market.,0.04478916898369789,0.7981491088867188,0.1570616066455841,negative,-0.7533599138259888
30,2012-10-15 03:52:00,"We expect the company to offer some visibility on the prevailing CRM market condition/trends, and update on its pipeline as well as guidance for the fourth quarter during the call.",0.09231703728437424,0.00577998161315918,0.9019030332565308,neutral,0.08653705567121506
31,2012-10-15 03:52:00,"We are currently Neutral on the stock, which carries a short-term Zacks #3 Rank (Hold).",0.016472836956381798,0.036079276353120804,0.9474478960037231,neutral,-0.019606439396739006
32,2012-10-15 03:52:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
33,2012-10-15 03:52:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
